Research programme: CNS disorders therapeutics - Sage Therapeutics
Alternative Names: Fragile X syndrome (FXS) therapy - Sage Therapeutics; PANAM platform - Sage Therapeutics; SAGE 105; SGE-202; SGE-301; SGE-516Latest Information Update: 28 Jun 2020
At a glance
- Originator Sage Therapeutics
- Developer SAGE Therapeutics
- Class Antidementias; Antidepressants; Antiepileptic drugs; Antipsychotics; Small molecules; Steroids
- Mechanism of Action GABA A receptor modulators; NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autistic disorder; Brain injuries; Dementia; Depressive disorders; Dravet syndrome; Fragile X syndrome; Multiple sclerosis; Pain; Post-traumatic stress disorders; Psychotic disorders; Rett syndrome; Schizophrenia; Seizures
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Dementia in USA
- 28 Jun 2020 No recent reports of development identified for preclinical development in Psychotic-disorders in USA
- 28 Oct 2018 No recent reports of development identified for preclinical development in Dravet-syndrome in USA (IM)